Rezolute Prices $100M Offering as Lead Drug Hits Phase 3 Efficacy Goal
RZLT has more than doubled off its 52-week low of $1.07 on elevated volume (2.7× avg).
Summary
Rezolute priced an underwritten offering of 22,040,976 shares at $3.87 plus pre-funded warrants for 3,800,000 shares at $3.869, raising roughly $100 million in gross proceeds. The pricing lands at essentially the current share price, so the deal is not a deep-discount dump — but it is large next to a company of this size and adds meaningful dilution. The cash is earmarked for commercialization preparation for ersodetug, working capital and general corporate purposes, and it comes days after the company filed a $400 million universal shelf and with cash down to $90.0 million at the end of the first fiscal quarter. Separately, preliminary upLIFT data in tumor hyperinsulinism show 13 of 16 enrolled patients met the responder threshold and 12 stopped intravenous glucose entirely, with no drug-related safety issues; one patient died of cancer progression and counts as a non-responder. Full study results, including the statistical analysis of the primary endpoint, are due mid-December 2026. The raise buys runway to push ersodetug toward filing, but it follows the November 2 sunRIZE miss in congenital hyperinsulinism, so the tumor indication now carries the story.
At the time of this announcement, RZLT was trading at $3.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $368.2M. The 52-week trading range was $1.07 to $11.17. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Benzinga.